Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.
about
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotypePaediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment ChoicesThe Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future PerspectivesUpdate on biomarkers in neuromyelitis opticaB Cells and Autoantibodies in Multiple SclerosisAnti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohortAntibody biomarkers in CNS demyelinating diseases - a long and winding roadAutoantibodies to MOG in a distinct subgroup of adult multiple sclerosisMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeMyelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India.Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.MOG antibody-associated diseasesMOG cell-based assay detects non-MS patients with inflammatory neurologic disease.Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritisB Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination.Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.Serological markers associated with neuromyelitis optica spectrum disorders in South India.MOG antibody-related disorders: common features and uncommon presentations.Mimics and chameleons of optic neuritis.Investigation-Directed Approach to Inflammatory Optic Neuropathies.Anti-myelin oligodendrocyte glycoprotein antibodies: Magnetic resonance imaging findings in a case series and a literature review.Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.MOG-IgG associated optic neuritis is not multiple sclerosis.Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases.Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease.Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.Defining distinct features of anti-MOG antibody associated central nervous system demyelination.MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.Antibodies to myelin oligodendrocyte glycoprotein are uncommon in Japanese opticospinal multiple sclerosis.Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report.
P2860
Q21146662-BDB0050E-5A2B-46B2-9B5A-57F1672C9343Q26748229-D41CDC89-CC00-48E1-A51D-75ADEF1BDDE9Q26767391-0BE40570-D601-406F-84D1-2E39E73D337DQ26799789-A64EA12F-166B-4E28-8CF4-BB62A817A6BDQ26801386-4BE848A9-67F5-43AE-81DE-75921317BF7EQ28256650-03E09FAA-3B80-4750-8530-E38752E73EB2Q28262403-3087A0CE-2311-492E-ACA6-393841BBBE70Q29036090-5F69A487-4479-488E-80DD-C0EBA0A4A542Q30371412-DDBADBD2-F7AA-4D5A-BBA8-88DD6DC74E02Q33645795-33729A93-7D69-4EF6-BD3D-F9B7A8C6BE91Q33693049-B090937E-59DF-4A9E-ACB1-F14AE83EEC20Q34486841-1B563BCA-67A2-472F-8EEB-77A17628517EQ35023345-C7269EF2-12A7-43F7-A209-9E29209F00B3Q35208073-B301060E-319A-46C4-876E-4CCC1A417E84Q35833865-5665F78A-2F19-4F93-B6CC-BCAAB258A89AQ35937581-07165C2D-2BD6-499C-B61A-8B8DAD79820DQ36261569-3BDB8FC1-EEA2-4BB2-B1E3-429461572E8DQ37374434-673862A9-B134-4A18-BF75-024F4FF334B0Q37383474-5C08176F-CD3F-45D0-8FF4-EE7950D2D91AQ37484413-E1D94ACD-C73F-47FA-8CD3-ADC2E6231DCDQ38645211-77F9B883-212A-400D-B6CE-61C7F62E0701Q38695978-1469FA35-3FF0-463E-B8BE-FC58BD7A6A76Q38766838-1FD6C7AE-B94C-4857-AFCA-519AA95B1E95Q38853499-9D67FE74-065C-43EB-8F8E-08B455CFB97FQ40545113-94550983-8C76-4C06-9BF3-B54B9009282CQ41106804-9DF659F5-359C-4613-82D0-DB3A49BDEB0FQ44875571-E7249BD7-4BDB-40DA-B889-BD8109915F6BQ47284937-BACF9006-AC53-4823-A406-8DF478733378Q47373538-72EDBDF5-0724-43CE-B4C9-E86385D0C1A1Q49336386-7C51F9DC-3C33-4286-80C2-A6D70593679AQ50263881-C2678FD2-850C-455E-9CD9-5EFE94018397Q50900378-55AFDA83-29D5-4C1A-AEC9-A5967580CADFQ51327401-07E51683-19F0-44FB-87BA-DA7C575D754AQ52152221-A7C17B16-4406-4CD1-9496-474A81541984Q52603606-7DC4B695-0998-49DD-AFC1-EDB8A3FC8BFAQ52648377-78B96A07-15BC-42C1-9470-EB04C256121EQ52803391-070A39AF-1712-489E-A4DB-973FB70109BAQ53249251-E9B2BC0F-CBB8-4EF0-9A96-161D90B6E89BQ53492453-62360035-5D90-46F3-BB1D-163CABB7C616Q55054339-136D05E8-11CF-426B-B06C-7A05A914B06D
P2860
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Antibodies to myelin oligodend ...... and recurrent optic neuritis.
@ast
Antibodies to myelin oligodend ...... and recurrent optic neuritis.
@en
Antibodies to myelin oligodend ...... and recurrent optic neuritis.
@nl
type
label
Antibodies to myelin oligodend ...... and recurrent optic neuritis.
@ast
Antibodies to myelin oligodend ...... and recurrent optic neuritis.
@en
Antibodies to myelin oligodend ...... and recurrent optic neuritis.
@nl
prefLabel
Antibodies to myelin oligodend ...... and recurrent optic neuritis.
@ast
Antibodies to myelin oligodend ...... and recurrent optic neuritis.
@en
Antibodies to myelin oligodend ...... and recurrent optic neuritis.
@nl
P2093
P2860
P1476
Antibodies to myelin oligodend ...... l and recurrent optic neuritis
@en
P2093
Andrew F Bleasel
Andrew Henderson
Con Yiannikas
David Booth
Fabienne Brilot
Graeme Stewart
John D E Parratt
Karrnan Pathmanandavel
Mahtab Ghadiri
Michael Barnett
P2860
P356
10.1212/NXI.0000000000000040
P577
2014-10-29T00:00:00Z